BEIJING, Oct. 28, 2024 /PRNewswire/ -- A report from China Daily
Shanxi province recently showcased its investment and trade opportunities to the European business community with promotional events held in the United Kingdom and Spain.
The events, running from Oct 7-15, were part of a large promotional campaign called Shanxi Brands on the Silk Road, a move aiming to enhance trade and investment cooperation between Shanxi and the countries and regions involved in the Belt and Road Initiative.
The events in the UK and Spain included exhibitions of products made in Shanxi, promotions of Shanxi's business opportunities and investment matchmaking activities. Shanxi's trade officials and business representatives also held talks with their counterparts in Britain and Spain, trying to tap into trade and investment opportunities.
On Oct 9, 29 companies from Shanxi, mostly manufacturers of activated carbon, filtering devices, pipes, valves and pumps, attended the Air Quality and Emissions and Water, Wastewater and Environmental Monitoring — which are known as AQE and WWEM — expos held at the National Exhibition Centre in Birmingham.
On Oct 10, the Shanxi delegation arrived in London, holding a trade and investment promotion event to boost multisector cooperation between Shanxi and the United Kingdom.
The event included activities to publicize Shanxi's business environment, industrial policies and investment opportunities, and exhibit Shanxi's industries and products, as well as matchmaking meetings between Shanxi's and Britain's enterprises.
The delegation also paid a visit to the London-based China-Britain Business Council, the UK's national business network promoting trade and investment with China. The two sides held talks and agreed to enhance exchanges and cooperation and help enterprises to develop in each other's markets.
On Oct 13, the Shanxi delegation held a trade and investment promotion event in Spain's coastal city of Barcelona, aiming to help Shanxi's businesses find opportunities to cooperate with their Spanish counterparts.
The delegation also held a meeting with the Spanish Confederation of Small and Medium Enterprises, aiming to enhance the exchanges and cooperation between SMEs from both sides.
Following the conclusion of the promotional events in the UK and Spain, many corporate delegates from Shanxi said the trips were a rare opportunity for business expansion in the two countries and across Europe as well.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
European tour opens up opportunities for Shanxi's businesses
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
